Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids.
The prevalence of posterior subcapsular cataracts in young patients receiving inhaled glucocorticoids for treatment of chronic asthma is unknown. In a cross-sectional study, slit-lamp examinations were done on 95 consecutive young patients who were taking inhaled beclomethasone or budesonide. No posterior subcapsular cataracts were found. The median age of the patients was 13.8 (range 5.8-24.8). The median dose of inhaled beclomethasone or budesonide was 750 micrograms/day (range 300-2000), or 12.9 micrograms/kg per day (range 7.5-34.2). The median duration of treatment was 5 years (range 1-15). 77% of the patients had not used oral glucocorticoids in the year preceding the examination. This study suggests that routine screening for posterior subcapsular cataracts in this patient population is not warranted.
Simons
F E
FE
Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Canada.
Persaud
M P
MP
Gillespie
C A
CA
Cheang
M
M
Shuckett
E P
EP
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects*; D001993:Bronchodilator Agents / Q000009:adverse effects*; D019819:Budesonide; D002386:Cataract / Q000139:chemically induced*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008350:Manitoba; D010349:Patient Compliance; D011282:Pregnenediones / Q000008:administration & dosage / Q000009:adverse effects*
D000336:Aerosols; D001993:Bronchodilator Agents; D011282:Pregnenediones; D019819:Budesonide; D001507:Beclomethasone